Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 30, 2007

Bavarian Nordic Obtains License to Vivalis’ ESC-derived Cell Lines

  • Vivalis granted Bavarian Nordic rights to evaluate the embryonic stem cell derived EBx® cells as a production platform of MVA-BN®-based (modified vaccinia Ankara-strain) vaccines.

    “We firmly believe that Vivalis’ chicken and duck EBx cell lines could be an attractive alternative to chicken embryonic fibroblasts for the industrial production of MVA-based vaccines,” says Franck Grimaud, CEO of Vivalis.

  • You’re all set! Thank you for subscribing to GEN Highlights.